AVO.L Regulatory News (AVO)

Free to access research and investor meetings in a post-MiFID2 world.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

Published to the market and investors on 16th April 2019 @ 7.03am (BST).

Advanced Oncotherapy Plc Recommendation: OUTPERFORMTarget Price: £1.55Current Price: 39.50p (CoB on 15th April 2019)

KEY TAKEAWAY

Advanced Oncotherapy ("AVO"), the developer of the LIGHT linear proton accelerator for the treatment of cancer patients, today announced the appointment of Moataz Karmalawy as Chief Commercial Officer. Joining from Varian Medical Systems, a major competitor, his appointment once again confirms the promise of AVO's proton therapy proposition; demonstrating that the company has reached an inflection point and is well on its way to commercialisation. Overall, the addition of Mr Karmalawy further strengthens AVO's robust management team which includes veterans of the PT industry from science, engineering, installation, application experience and compliance. We reiterate both our OUTPERFORM recommendation and our target price ("TP") of GBp 155.

Commercialisation now within view

The appointment of Mr Karmalawy as Chief Commercial Officer adds an experienced industry veteran to AVO's management. With senior management experience at industry heavyweights Philips Healthcare and Varian Medical Systems, Mr Karmalawy brings on-board significant business operational experience which will be vital in securing a successful commercialisation roll-out for the LIGHT system. With the successful integration and subsequent testing of the LIGHT system at 52MeV in late 2018, the LIGHT project was significantly de risked with several further developmental milestones expected in 2019E. The company expects to reach therapeutically-relevant energy levels of 250MeV by YE2019. His appointment marks another promising step in AVO's execution plan as the appointment of such a prominent hire indicates a paradigm shift from a focus on developing the platform to marketing and commercialisation.

Proven success in the commercialisation of particle therapy systems

Having joined Varian in 2007, Mr Karmalawy has been an integral part of the Varian particle therapy business for the last 12 years, overseeing the growth of the division. As General Manager, World Wide Particle Therapy Treatment, he has experience across all aspects of the particle therapy business including business development, supply chain management and M&A activities. Mr Karmalawy also brings a history of successful commercialisation exercises in America, which represents a key target market for AVO that has remained largely under penetrated.

Top calibre management to drive commercial success

AVO's management team consists of high calibre industry veterans, from across science, engineering, installation, application experience and compliance. We feel that the successful industrialisation of LIGHT will be grounded in experience of top professionals like Prof. Stephen Myers, Ed Lee, Dr. Jonathan Farr and Dr. Michel Baelen, supported by a team that has the right credentials to implement an attractive funding and execution strategy such as Dr. Mike Sinclair and Nicolas Serandour.

With the development timeline on schedule and first patients due to be treated in H2/2020E, we believe that AVO offers strong upside potential coinciding with successful early stage roll-out of the LIGHT system. We reiterate both our OUTPERFORM recommendation and our TP GBp 155.

Kind regards,

Martin Piehlmeier | AnalystKieron Banerjee | Analyst Trainee

goetzpartners Healthcare Research Team | Research Team

goetzpartners securities Limited

The Stanley Building, 7 Pancras Square, London, N1C 4AG, England, UK.

T +44 (0) 203 859 7725 | T +44 (0) 203 859 7728 | martin.piehlmeier@goetzpartners.com / kieron.banerjee@goetzpartners.com / healthcareresearch@goetzpartners.com

www.goetzpartnerssecurities.com

goetzpartners securities LinkedIn page

Registered in England No. 04684144.

Managing Directors: Dr Stephan Goetz, Martin Brunninger and Ulrich Kinzel.

goetzpartners securities Limited - Team Members

Equity Research Analysts - Martin Brunninger, Brigitte de Lima, Chris Redhead, Martin Piehlmeier and Kieron Banerjee.Sales / Marketing - Erland Sternby.Corporate Finance - Ulrich Kinzel, Wolf Dornbusch and Youchen Xin.Corporate Access and IR - Tanya Tracey and Bettina Ellinghorst.Compliance / Research Production - Paul W. Dunne.

Click here to see our privacy policy.

GPSL has a formal client relationship with Advanced Oncotherapy Plc.

GPSL publishes and distributes "Investment" Research and "Corporate Sponsored" Research. Our Corporate Sponsored Research and investor meetings (e.g. NDRs, 1 to 1 meetings) are free to access and attend and is not classified as an inducement in a post-MiFID2 world, this is because the issuer is paying GPSL. GPSL does not offer any execution or market making services. This is a marketing communication as defined by the Financial Conduct Authority ("FCA"). The information herein is considered to be an acceptable minor non-monetary benefit as defined under FCA COBS 2.3A19(5).

In accordance with the General Data Protection Regulation ("GDPR") - if you would like to be removed / unsubscribed from our CRM (also please note that you are free to contact GPSL at any time in the future to have your e-mail subscription amended), please e-mail:researchproduction@goetzpartners.com

About GPSL: goetzpartners securities Limited is a member of the goetzpartners group, and a leading pan European investment bank and research company. We bring together a wide range of expertise, insights and innovations to advance the interests of our clients around the world. The fast-changing environment brings challenges for businesses and investors. Research innovation, digital transformation and disruptive business ideas reshuffle the corporate world at a relentless pace. Our sector knowledge and our global footprint bring together corporate intelligence and a deep understanding of the industry with a wide network of top decision makers. These collective insights help our clients to stay at the leading edge of change.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

This communication (including any attachments) from goetzpartners securities Limited ("GPSL") is confidential and may contain information which is proprietary, privileged or otherwise legally protected against unauthorised use or disclosure. If you receive this communication in error or are not the intended recipient of this communication, please delete and destroy all copies in your possession, notify the sender that you have received this communication, and note that any review or dissemination of, or the taking of any action in reliance on this communication is expressly prohibited. GPSL shall not be liable for the improper or incomplete transmission of the information contained in this communication nor for any delay in its receipt or damage to your system. GPSL does not guarantee that the integrity of this communication has been maintained nor that this communication is free of viruses, interceptions or interference and makes no warranties in relation to these matters. This is not an offer or a solicitation to buy or sell securities or investment products, or an official confirmation. GPSL record electronic and phone communications in accordance with FCA and MiFID2 regulations, they will be monitored for regulatory and training purposes. GPSL is authorised and regulated by the Financial Conduct Authority of the United Kingdom (Firm Reference Number: 225563).

Click on the following link for the GPSL MiFID2 Investor Guidance Notice

GPSL Equity Research publications are available on the following aggregators and via news distribution circuits (For Institutional Use Only): AlphaMetry, AlphaSense, Bloomberg (GOET), Capital IQ, EQS, FACTSET, ResearchFN, Research Tree, RNS Reach, Sentieo and Thomson Reuters.

Please copy the below link and paste it into your browser for the full pdf version of the equity research report:

https://gp.bluematrix.com/sellside/EmailDocViewer?encrypt=8fb16bbf-0f76-4d6f-8b54-a78cd99ec200&mime=pdf&co=gp&id=paul.dunne@goetzpartners.com&source=libraryView

Free to access research and investor meetings in a post-MiFID2 world.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.